Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Iron Med RX vs Medro

Iron Med RX
Graded #454

Lower grade

vs+8.800000000000004
Medro
Graded #256

Higher grade

The verdict

Medro takes it — 63.6/100 to 54.8/100.

Medro grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Medro (Medro Health Technologies, Inc.) is a telehealth brand whose GLP-1 program offers compounded semaglutide and tirzepatide, plus brand-name GLP-1s when eligible, via a partner medical group and…

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueMedro +5
45
50
Dose & formulationMedro +26
51
77
Clinical oversightEven
71
71
Labs & monitoringEven
52
52
FulfillmentMedro +34
58
92
Contract termsIron Med RX +22
55
33
Iron Med RX · left barMedro · right bar

The numbers

MetricIron Med RXMedro
WeighScore54.8/10063.6/100
GradeCC
Scorecard rank#454#256
SemaglutideNot disclosed$199/mo (compounded)
TirzepatideNot disclosed$299/mo (compounded)
CoverageCoverage not publishedAll 50 states
Brand-name accessCompounded onlyYes
Oral / sublingualYesInjection only
Iron Med RX

Graded #454 · C

Strengths

  • Unusually broad GLP-1 lineup — compounded semaglutide and tirzepatide in both oral tablets and injection, plus microdosing and longevity add-ons
  • Online process with licensed-provider oversight, virtual consults, progress tracking and home delivery
  • Oral tablet options for people who would rather not inject

Where it loses points

  • Prices are not shown publicly — you only see costs after creating an account, so you cannot compare value upfront
  • Labels its oral semaglutide 'research-grade' — wording usually tied to research/non-prescription peptides; confirm it is prescribed for human use
  • Does not name its compounding pharmacy or list the states it serves; the listed address is a private mailbox (PMB), not a clinic
  • Compounded GLP-1 only — no brand-name or insurance options; small, lightly documented operation
Medro

Graded #256 · C

Strengths

  • Covers both compounded semaglutide and tirzepatide and can prescribe brand-name GLP-1s when clinically appropriate.
  • LegitScript-certified (seal #50716646), available in all 50 states, with tiered pricing shown before checkout.
  • No membership fee and free expedited shipping on all orders; online intake with no appointment required in many cases.
  • Prices drop with longer commitments (semaglutide to $149/mo, tirzepatide to $224/mo on a 12-month plan).

Where it loses points

  • Does not name its compounding pharmacy or its clinical partner medical group, so the fulfillment chain is not verifiable.
  • Pricing is described as illustrative and may change by dose, pharmacy availability, and eligibility — final cost shows only at checkout.
  • Very new brand (2026, trademark pending) spanning many verticals, with a short track record in GLP-1 care.
  • Compounded medications are not FDA-approved or therapeutically equivalent to Ozempic, Wegovy, Mounjaro, or Zepbound.

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard